BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Medeni SS, Namdaroglu S, Cetintepe T, Ozlu C, Tasli F, Adibelli ZH, Bilgir O, Tatar E. An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment. Hematol Rep 2018;10:7553. [PMID: 30344987 DOI: 10.4081/hr.2018.7553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Tatar E, Erdi ZC, Ozgur O, Tasdemir A, Tatar B. Importance of eculizumab treatment in recurrence of atypical hemolytic uremic syndrome during the SARS-CoV-2 pandemic. Int Urol Nephrol 2021. [PMID: 34003430 DOI: 10.1007/s11255-021-02890-y] [Reference Citation Analysis]
2 Racchiusa S, Mormina E, Ax A, Musumeci O, Longo M, Granata F. Posterior reversible encephalopathy syndrome (PRES) and infection: a systematic review of the literature. Neurol Sci 2019;40:915-22. [PMID: 30604335 DOI: 10.1007/s10072-018-3651-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]